Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Public ClinicalTrials.gov record NCT00412893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
Study identification
- NCT ID
- NCT00412893
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 527 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2007 (Actual)
- Primary completion
- Mar 28, 2013 (Actual)
- Completion
- Mar 28, 2013 (Actual)
- Last update posted
- Dec 10, 2024
2007 – 2013
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294-0006 | — |
| University of California at San Francisco | San Francisco | California | 94143 | — |
| University of Chicago, Division of Infectious Diseases | Chicago | Illinois | 60637 | — |
| Indiana BMT | Springfield | Illinois | 62703 | — |
| Springfield Clinic LLP | Springfield | Illinois | 62703 | — |
| Infectious Disease of Indiana | Indianapolis | Indiana | 46280 | — |
| Brigham & Womens Hospital | Boston | Massachusetts | 02115 | — |
| Not listed | Worcester | Massachusetts | 01655 | — |
| Upstate Infectious Diseases Association LLP | Albany | New York | 12208 | — |
| Regional Infection Diseases Infusion Center Inc. | Lima | Ohio | 45801 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 96 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00412893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00412893 live on ClinicalTrials.gov.